Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of 3G10 in adults with elevated lipoprotein(a) and arterial inflammation
NL-OMON44302Phase 2Active, not recruiting
- Sponsor
- Athera Biotechnologies AB
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease and arteritis comparing 3G10 with Placebo (2 arms). Primary endpoint: Change in TEM in monocytes. Started Dec 2017; status: active, not recruiting.
02
Drugs
ABR-001
03
Conditions
atherosclerotic diseasearteritis
Beyond the preview
Go deeper on NL-OMON44302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44302.